Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.

Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS.

Sci Signal. 2009 Dec 15;2(101):ra82. doi: 10.1126/scisignal.2000446.

2.
3.

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

Roth P, Weller M.

Neuro Oncol. 2014 Oct;16 Suppl 8:viii14-9. doi: 10.1093/neuonc/nou222. Review.

4.

Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.

Gao Q, Lei T, Ye F.

Expert Opin Investig Drugs. 2013 Aug;22(8):1023-40. doi: 10.1517/13543784.2013.806484. Epub 2013 Jun 4. Review.

PMID:
23731170
5.

Epidermal growth factor receptor as a therapeutic target in glioblastoma.

Kalman B, Szep E, Garzuly F, Post DE.

Neuromolecular Med. 2013 Jun;15(2):420-34. doi: 10.1007/s12017-013-8229-y. Epub 2013 Apr 11. Review.

PMID:
23575987
6.

Targeting SREBP-1-driven lipid metabolism to treat cancer.

Guo D, Bell EH, Mischel P, Chakravarti A.

Curr Pharm Des. 2014;20(15):2619-26. Review.

7.

Erlotinib: early clinical development in brain cancer.

Addeo R, Zappavigna S, Parlato C, Caraglia M.

Expert Opin Investig Drugs. 2014 Jul;23(7):1027-37. doi: 10.1517/13543784.2014.918950. Epub 2014 May 16. Review.

PMID:
24836441
Items per page

Supplemental Content

Write to the Help Desk